[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Renmin Hospital of Wuhan University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":494},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,42,73,99,120,147,173,193,218,246,271,292,315,337,362,381,401,422,446,467],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100599494","digital-out-of-hospital-management-on-clinical-outcomes-in-patients-with-early-cardiogenic-shock-100599494",false,"NCT07085221","Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock","Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock: a Multi-center, Randomized Controlled Clinical Trial","DIGI-CS","Inclusion Criteria\n\n1. Age ≥ 18 years old;\n2. The patient meets the diagnosis of early-stage cardiogenic shock, with SCAI stage A, B, or C during hospitalization; (1) SCAI stage A:\n\nWithout signs of shock and meeting one of the following criteria:\n\n1. Combined with extensive myocardial infarction, diagnosed as widespread anterior wall myocardial infarction based on ST-segment elevation in ECG leads (V1-V5, aVL, I leads), inferior wall combined with right ventricular (II, III, aVF, V3R-V5R leads) and\u002For posterior wall myocardial infarction (V7-V9 leads), or recurrent myocardial infarction within 28 days.\n2. Concurrent acute heart failure or acute exacerbation of chronic heart failure. (2) SCAI stage B-C (meeting the following conditions)\n\n1\\) 60 \\\u003C SBP \\\u003C 90 mmHg or mean arterial blood pressure 50 \\\u003C MAP \\\u003C 60 mmHg or a decrease of \\> 30 mmHg from baseline lasting 30 minutes; or SBP ≥ 90 mmHg but heart rate \u002FSBP \\> 1 lasting \\> 30 minutes.\n\n2\\) The highest arterial blood lactate during hospitalization \\\u003C 5 mmol\u002FL. 3. Stable clinical symptoms at discharge, defined as:\n\n1. SBP ≥ 90 mmHg when vasoactive drugs are not used;\n2. No signs and symptoms of shock. 4. Understand and be willing to sign the informed consent, and be willing to follow the treatment and visit plan required by the protocol.\n\nExclusion Criteria\n\n1. Unable to use a smartphone for out-of-hospital management despite training\n2. The reasons for discharge were treatment withdrawal and transfer to another hospital for continued therapy\n3. Previous or current hospital admission due to cardiac arrest\n4. Refractory cardiogenic shock\n5. Refractory Heart Failure (ACC\u002FAHA guidelines Stage D heart Failure)\n6. Left ventricular ejection fraction \\\u003C 30%\n7. (Estimated) glomerular filtration rate \\\u003C 25 ml\u002Fmin or on dialysis\n8. Severe hepatic insufficiency (Child-Pugh class C)\n9. Severe chronic obstructive pulmonary disease (confirmed by pulmonary function tests, or requiring long-term home oxygen therapy or long-term use of corticosteroids)\n10. History of cardiac surgery\n11. Pregnant or lactating women\n12. Combined with malignant tumors and other serious diseases, the expected life span is less than 1 year\n13. Neuropsychiatric disorders, unable to cooperate with management;\n14. Participation in other clinical trials within the past year;\n15. Other circumstances considered to be inappropriate for this study by the investigator.","ALL","18 Years",{"count":20,"type":21},472,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical study was a multi-center, open-label, randomized controlled clinical trial. A total of 472 patients with early-stage cardiogenic shock were recruited and randomly divided into the experimental group and the control group, with 236 cases in each group. The HeartMed-HF digital out-of-hospital management was used to manage the patients in the experimental group, while the patients in the control group were managed according to the discharge guidance. The primary endpoints were 1-year all-cause mortality and unplanned readmission after randomization (excluding emergency department visits). Secondary endpoints (at 3 months, 6 months, and 12 months post-randomization) were: all-cause mortality, rehospitalization for HF, recurrent MI, ischemia-driven repeat revascularization, stroke, BARC 3-5 grade major bleeding, unplanned formal rehospitalization, types of GDMT medications or GDMT target dose achievement rate.",[27,28],"Shock, Cardiogenic","Shock","RECRUITING","2026-06-15",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":33},"2025-07-26",{"date":37,"type":21},"2028-12-31",{"name":39,"class":40},"Renmin Hospital of Wuhan University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100640738","low-intensity-focused-ultrasound-targeting-the-stellate-ganglion-for-regulating-autonomic-nerve-function-and-sleep-quality-in-perioperative-patients-with-cardiovascular-diseases-100640738","NCT07595068","Low-Intensity Focused Ultrasound Targeting the Stellate Ganglion for Regulating Autonomic Nerve Function and Sleep Quality in Perioperative Patients With Cardiovascular Diseases","Low-Intensity Focused Ultrasound Targeting the Stellate Ganglion for Regulating Autonomic Nerve Function and Sleep Quality in Perioperative Patients With Cardiovascular Diseases: A Multicenter, Double-Blind, Randomized Controlled Trial","US-REST","Inclusion Criteria:\n\n1. Diagnosed with cardiovascular disease (CVD) and scheduled to undergo cardiology-related surgical treatment\n2. Able to receive and tolerate the aforementioned cardiology-related surgical treatment\n3. Aged between 18 and 79 years (inclusive), with no restriction on gender\n4. Agree to accept random allocation of the treatment strategies\n5. With clear consciousness, no severe mental disorders or cognitive impairment; voluntarily sign the written informed consent form (ICF) and are willing to actively cooperate with the study treatment\n\nExclusion Criteria:\n\n1. Have used sedative-hypnotic drugs, antipsychotic drugs, opioid analgesics, antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), central nervous system (CNS) stimulant drugs, or any other medications that alter sleep architecture within the past 30 days\n2. Have a history of cervical infection, trauma, severe cervical deformity, or prior cervical surgery\n3. Unable to complete the daily study intervention as required by the trial protocol\n4. Are participating in another clinical trial, or have participated in other clinical trials with interventions that may interfere with the results of this study\n5. Have undergone major surgery or general anesthesia within the past 30 days\n6. Have a history of alcohol abuse\n7. Are female subjects who are pregnant or lactating, or plan to become pregnant during the study period\n8. Have severe cognitive impairment, severe psychiatric disorders, epilepsy, or other related neurological disorders\n9. Have concomitant malignant tumor or severe dysfunction of vital organs\n10. Have active systemic infection\n11. Have significant bleeding tendency, or renal failure undergoing regular hemodialysis\n12. Are deemed unsuitable for the trial by the investigator for any other reason -","79 Years",{"count":52,"type":21},200,[24],"The goal of this multicenter, double-blind, randomized controlled trial is to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) stellate ganglion modulation for improving autonomic function and sleep quality in perioperative cardiovascular disease patients.\n\nThe main questions it aims to answer are:\n\n1. Does LIFU improve heart rate variability and sleep characteristics from baseline at 3-7 days post-surgery compared to sham ultrasound?\n2. Does LIFU improve serological markers, vital signs, Pittsburgh Sleep Quality Index (PSQI), and reduce \\>30-second perioperative arrhythmias?\n3. What is the safety profile of LIFU in this population? 200 eligible patients will be randomized 1:1 to receive either active LIFU (2.0W, 1MHz, 50% duty cycle, 30min daily for 3-7 days) plus standard care, or identical sham ultrasound plus standard care. A four-party double-blind design (subjects, operators, assessors, analysts) will be implemented. The study will run from May 1, 2026 to April 1, 2027 at 6 centers in China.\n\nParticipants will:\n\n1. Complete pre-surgery screening and baseline assessments (PSQI, 12h ECG\u002Fsleep monitoring, residual blood sample collection)\n2. Receive daily assigned ultrasound intervention for 3-7 consecutive days post-surgery\n3. Undergo 72h continuous ECG monitoring post-surgery, and repeat assessments at 3-7 days\n4. Have all adverse events and arrhythmias recorded throughout the study\n5. May withdraw voluntarily at any time without affecting routine medical care",[56],"Diagnosed With Cardiovascular Diseases and Scheduled to Undergo Interventional Cardiology Procedures",[58,59,60,61,62],"Low-Intensity Focused Ultrasound","Cardiovascular Diseases","Stellate Ganglion","Autonomic Nervous Function","Sleep Quality","NOT_YET_RECRUITING","2026-05-12",{"date":66,"type":33},"2026-05-19",{"date":68,"type":21},"2026-05-05",{"date":70,"type":21},"2027-04-01",{"name":39,"class":40},7,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":98,"locationsCount":72},"100640889","efficacy-and-safety-of-ultrasound-modulation-of-stellate-ganglion-for-the-prevention-of-ventricular-arrhythmia-in-patients-with-st-segment-elevation-myocardial-infarction-100640889","NCT07587294","Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patients With ST-segment Elevation Myocardial Infarction","Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patients With ST-segment Elevation Myocardial Infarction: A Multicenter, Double-blind Randomised Controlled Trial","US-PRAY","Inclusion Criteria:\n\n1. Age between 18 and 80 years (including 18 and 80 years); gender is not restricted;\n2. Agree to be randomly assigned to a treatment strategy and be able to undergo follow-up as required;\n3. Patients with a clinical diagnosis of acute ST-segment elevation myocardial infarction;\n4. Presented within 12 hours of symptom onset and underwent PCI;\n5. Killip functional class I-III;\n6. Agree to participate in this study and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients with a history of myocardial infarction;\n2. Patients with a history of cardiac pacemaker or implantable cardioverter-defibrillator (ICD) implantation;\n3. Patients with severe bradycardia or high-degree atrioventricular block;\n4. Patients with severe heart failure (left ventricular ejection fraction \\\u003C30%);\n5. Patients with cardiogenic shock (Killip Class IV);\n6. Patients admitted with frequent ventricular fibrillation or cardiac arrest;\n7. Patients with a history of malignant hematological disorders or renal failure (estimated eGFR \\\u003C30 ml\u002Fmin);\n8. Patients with skin lesions, infections, or benign or malignant tumors in the left neck;\n9. Pregnant or breastfeeding women, or women planning to become pregnant during the study;\n10. Patients with severe cognitive impairment, psychiatric disorders, epilepsy, etc.;\n11. Patients with concurrent malignant tumors or diseases of vital organs;\n12. Patients with active systemic infections;\n13. Patients who have participated in other drug or medical device clinical trials within the past 3 months;\n14. Patients who are unable or unwilling to provide informed consent;\n15. Patients deemed unsuitable for participation in this clinical trial by the investigator.","80 Years",{"count":83,"type":21},100,[24],"The goal of this multicenter, double-blind, randomized controlled trial is to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) stellate ganglion modulation for preventing ventricular arrhythmias after ST-segment elevation myocardial infarction (STEMI) in patients undergoing percutaneous coronary intervention (PCI).\n\nThe main questions it aims to answer are:\n\n1. Does LIFU reduce the frequency and duration of ventricular arrhythmias within 72 hours post-PCI compared to sham ultrasound?\n2. Does LIFU improve electrophysiological stability, myocardial injury markers, cardiac function and heart rate variability, and reduce inflammatory markers and sympathetic neurotransmitters?\n3. What is the safety profile of LIFU in this population?\n\n100 eligible patients will be randomized 1:1 to receive either active LIFU (2.0W, 1MHz, 50% duty cycle, 30min per session: 1 intra-PCI session + 7 daily post-PCI sessions) plus standard care, or identical sham ultrasound plus standard care. A comprehensive double-blind design (subjects, operators, assessors, statisticians) will be implemented. The study will run from May 2026 to April 2027 at 7 centers in China, led by Renmin Hospital of Wuhan University.\n\nParticipants will:\n\n1. Complete pre-PCI screening and baseline assessments (informed consent, demographic\u002Fmedical history, physical examination, electrocardiogram, echocardiogram, blood sample collection) within 12 hours of symptom onset\n2. Receive 1 assigned ultrasound intervention during PCI, followed by 1 daily intervention for 7 consecutive days postoperatively\n3. Undergo 72h continuous ECG monitoring post-PCI, blood sampling at baseline and postoperative days 1, 3, 7, and echocardiography assessment at postoperative day 7\n4. Have all adverse events and arrhythmias recorded throughout the study\n5. May withdraw voluntarily at any time without affecting routine medical care",[87],"Acute ST-segment Elevation Myocardial Infarction (Patients Undergoing Emergency PCI)",[89,90,91,92,93],"Ultrasound","Stellate ganglion","Neuromodulation","STEMI","Ventricular arrhythmia",{"date":95,"type":33},"2026-05-14",{"date":68,"type":21},{"date":70,"type":21},{"name":39,"class":40},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":41},"100598587","application-evaluation-research-on-the-artificial-intelligence-assisted-support-system-for-the-diagnosis-of-colorectal-tubular-adenoma-lesions-100598587","NCT07073430","Application Evaluation Research on the Artificial Intelligence-assisted Support System for the Diagnosis of Colorectal Tubular Adenoma Lesions","Inclusion Criteria:\n\n* Patients aged ≥ 18 years, who need to undergo colonoscopy, regardless of gender.\n* Voluntarily sign the informed consent form\n* Promise to abide by the research procedures and cooperate in the implementation of the entire research process.\n\nExclusion Criteria:\n\n* Patients who has a history of abdominal or pelvic surgery or radiotherapy in the past;\n* Patients who has definite active lower gastrointestinal bleeding.\n* Existing or suspected hereditary colorectal polyposis, inflammatory bowel disease;\n* Uncontrolled hypertension (systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 95 mmHg after standardized treatment)\n* There is a history of stroke, coronary artery disease, or vascular disease;\n* Pregnant;\n* Intestinal preparation cannot be carried out.",{"count":106,"type":21},4000,"OBSERVATIONAL","This study is a prospective,multi-center and observational clinical study.Investigators would like to innovatively construct a \"trinity\" database of colorectal tubular adenomas based on white light - magnifying chromo - pathological images.It simulates the decision - making logic of doctors, and based on the multimodal endoscopic LAFEQ method previously proposed, develop a multimodal deep - learning diagnostic model for colon adenomas and an interpretable risk prediction model for intestinal adenomas. While achieving high - precision auxiliary treatment decisions, clearly present the decision - making basis, and break through the limitation of poor interpretability of previous medical imaging AI models.",[110,111],"Colorectal Adenoma","Artificial Intelligence (AI)","2026-03-21",{"date":114,"type":33},"2026-03-25",{"date":116,"type":33},"2023-11-28",{"date":118,"type":21},"2026-10-31",{"name":39,"class":40},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":126,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":41},"100613662","evaluation-of-the-efficacy-and-safety-of-an-intensified-strategy-of-intratonsillar-immunotherapy-itit-for-allergic-rhinitis-a-multicenter-randomized-double-blind-controlled-trial-100613662","NCT07269509","Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhinitis: A Multicenter, Randomized, Double-blind, Controlled Trial","Inclusion Criteria:\n\n1. Voluntary signing of the informed consent form\n2. Commitment to abide by the research procedures and cooperate throughout the implementation of the research\n3. Diagnosis conforms to the ARIA guidelines. The basis for the diagnosis is as follows: a. Symptoms: Paroxysmal sneezing, clear nasal discharge, nasal itching, and nasal congestion occur for 2 or more times, with symptoms persisting or accumulating for more than 1 hour each day, accompanied by tearing, eye itching, and eye redness and other ocular symptoms; b. Signs: Commonly, the nasal mucosa is pale and edematous, and nasal watery secretions are present; c. Allergen testing: Positive results for dust mite allergens SPT and\u002For serum-specific IgE, or positive nasal challenge test, requiring Der p and Der f to be positive (SPT results of ++ or higher, serum sIgE ≥ 2 grades), and other allergens in the allergen test to be negative\n4. History of allergic rhinitis caused by atopic dust mite allergens\n5. Infertile women must ensure they do not become pregnant during the treatment period\n6. Age must be between 5 and 60 years old\n\nExclusion Criteria:\n\n1. Allergic to the excipients of Arrogel (aluminum hydroxide) or the rescue medication epinephrine\n2. Suffering from respiratory system diseases other than stable asthma\n3. Pulmonary dysfunction (NYHA grade II or above, or FeV1 \\\u003C 70%) or having irreversible pathological changes in the reactive organs such as emphysema or bronchiectasis\n4. Severe acute or chronic diseases (including malignant diseases), inflammation and fever\n5. Multiple sclerosis\n6. Immune system diseases (autoimmune diseases, immune diseases caused by antigen-antibody complexes, immune deficiencies, etc.)\n7. Active pulmonary tuberculosis\n8. Severe mental disorders\n9. Obvious cardiac dysfunction\n10. Patients who have received immunotherapy within the last 1 years (subcutaneous injection or sublingual administration of allergen-specific immunotherapy, etc.)\n11. Patients who used experimental drugs or participated in other clinical studies within 30 days before treatment\n12. Patients who received IgE monoclonal antibody (mAb) treatment in the past 4 months\n13. Patients taking beta-blockers\n14. Patients who have insufficient understanding of the trial\n15. Patients whose age is not between 5 years old and 65 years old\n16. Patients who are pregnant or breastfeeding during the study period, or have plans to get pregnant\n17. Patients who cannot undergo tonsil injection due to acute or chronic tonsillitis, small tonsils, previous tonsillectomy, overly sensitive pharyngeal reflex and inability to cooperate with treatment\n18. Patients with aphthous stomatitis","5 Years","65 Years",{"count":129,"type":21},276,[24],"This is a multicenter, randomized, double-blind, controlled trial to evaluate the efficacy and safety of an enhanced strategy of allergen-specific immunotherapy (ITIT) in the treatment of allergic rhinitis. By recording the changes in CSMS from baseline to post-treatment in the subjects and the incidence of adverse reactions after treatment, the differences in efficacy and safety between the patients who received the basic three doses and those who received booster injections were compared. Furthermore, the impact of different booster strategies on long-term efficacy was compared to optimize the injection strategy. At the same time, the influence of different administration procedures on the immune response was evaluated.",[133],"Allergic Rhinitis",[135,136,137,138],"Allergic rhinitis","Intratonsillar","Allergen immunotherapy","Standardized dust mite allergen extracts","2025-11-25",{"date":141,"type":33},"2025-12-08",{"date":143,"type":21},"2025-12-30",{"date":145,"type":21},"2029-02-28",{"name":39,"class":40},{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":154,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":4},"100604595","phase-2-efficacy-and-safety-of-two-bladder-preserving-treatment-durations-with-disitamab-vedotin-plus-toripalimab-combination-in-her2-expressing-muscle-invasive-bladder-cancer-a-phase-ii-open-label-randomized-clinical-trial-100604595","NCT07151560","Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial","Disitamab Vedotin Plus Toripalimab for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial","Inclusion Criteria:\n\n1. Voluntary agreement to participate in the study and provision of signed and dated informed consent form.\n2. Male or female, aged ≥ 18 years.\n3. Life expectancy of ≥ 18 months.\n4. Pathologically and radiologically confirmed diagnosis of muscle-invasive bladder cancer (MIBC), clinical stage cT2-4aN0M0.\n5. Ability to provide tumor tissue specimen from the primary site for HER2 testing; HER2 expression of IHC 1+, 2+, or 3+.\n6. No prior systemic therapy for bladder cancer.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n8. Adequate cardiac, bone marrow, hepatic, and renal function (as per the reference ranges of the investigating center).\n\nExclusion Criteria:\n\n1. History of malignancies other than urothelial carcinoma, with the following exceptions:Patients who have received potentially curative therapy and have no evidence of the disease for 5 years.Adequately treated basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, or other in situ carcinomas that have undergone curative resection.\n2. Conditions affecting drug absorption, distribution, metabolism, or excretion.\n3. Prior allogeneic stem cell or solid organ transplantation.Prior systemic anti-cancer therapy (including Chinese herbal medications with anti-cancer indications).Less than 4 weeks between the completion of prior therapy and the first dose of study treatment, or presence of persistent adverse events from previous treatments that have not recovered to ≤ Grade 1 per CTCAE (excluding alopecia or pigmentation).\n4. History or current presence of congenital or acquired immunodeficiency diseases.\n5. Active or documented history of autoimmune or inflammatory disorders.",true,{"count":156,"type":21},60,[158],"PHASE2","This study aims to evaluate the efficacy of disitamab vedotin combined with toripalimab as a bladder-preserving treatment combination in patients with HER2 positive locally advanced MIBC, including one year bladder-intact DFS (BI-DFS) and safety.",[161],"Urology",[163,164],"Bladder-preserving","Disitamab Vedotin","2025-08-25",{"date":167,"type":33},"2025-09-03",{"date":169,"type":21},"2025-08-30",{"date":171,"type":21},"2030-08-30",{"name":39,"class":40},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":180,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":192,"locationsCount":41},"100547291","artificial-intelligence-assisted-system-in-colonoscopy-100547291","NCT06406062","Artificial Intelligence-assisted System in Colonoscopy","To Evaluate the Effectiveness and Safety of an Artificial Intelligence-assisted System in Colonoscopy in a Real-world Obsevational Multicenter Study","Inclusion Criteria:\n\n1. age \\> 50 years old;\n2. required diagnostic colonoscopy, screening colonoscopy, or follow-up colonoscopy;\n3. voluntarily sign informed consent;\n4. Commitment to abide by the study procedures and cooperate with the implementation of the whole process of the study.\n\nExclusion Criteria:\n\n1. have participated in other clinical trials, signed informed consent and are in the follow-up period of other clinical trials;\n2. known polyposis syndrome patients;\n3. patients with known IBD;\n4. patients considered by the investigators to be unsuitable or unable to undergo complete digestive endoscopy and related examinations;\n5. high-risk diseases or other special conditions considered by the investigator to be unsuitable for clinical trial participation.","50 Years",{"count":182,"type":21},7500,"In recent years, computer-aided diagnosis system based on artificial intelligence (AI) has been used in colorectal polyp detection. In recent years, computer-aided diagnosis system based on artificial intelligence (AI) has been used in colorectal polyp detection. However, whether AI-assisted can improve the adenoma-detection rate (ADR) is inconclusive. This study aims to evaluate the real-world performance of an AI system that combines polyp detection with colonoscopy quality control.\n\nThis study aims to explore the clinical application value of AI-based polyp detection and quality control function by comparing the data of polyp detection rate and adenoma detection rate in multiple centers with and without AI-assisted colonoscopy in a multicenter, prospective real world study. However, whether AI-assisted can improve the adenoma-detection rate (ADR) is inconclusive. This study aims to evaluate the real-world performance of an AI system that combines polyp detection with colonoscopy quality control.\n\nThis study aims to explore the clinical application value of AI-based polyp detection and quality control function by comparing the data of polyp detection rate and adenoma detection rate in multiple centers with and without AI-assisted colonoscopy in a multicenter, prospective real world study.",[185],"Adenoma Colon Polyp","2025-04-09",{"date":188,"type":33},"2025-04-13",{"date":190,"type":33},"2024-05-20",{"date":143,"type":21},{"name":39,"class":40},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":199,"targetDuration":201,"studyType":107,"phases":4,"briefSummary":202,"conditions":203,"keywords":205,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":217,"locationsCount":41},"100507974","influence-mechanism-of-tumor-microenvironment-changes-on-neoadjuvant-therapy-for-esophageal-squamous-cell-carcinoma-100507974","NCT05894369","Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma","Inclusion criteria：\n\nThe patient's age between 18 to 80 years old; Esophageal squamous cell carcinoma with definite pathological diagnosis and II-IVA clinical stage Preoperative neoadjuvant chemotherapy combined with immunotherapy The score of eastern cooperative oncology group is 0 \\~ 1 Exclusion criteria\n\nThe estimated survival time is less than 6 months; The first diagnosis had distant metastasis Suffering from malignant tumor or accompanying malignant disease in the past 5 years Pregnant or pregnant women. Vulnerable groups (those without informed ability, minors, vagrants, students and subordinates of researchers, employees of bidders)",{"count":200,"type":21},10,"1 Year","To evaluate the predictive value and mechanism of inflammatory factors in peripheral blood on the prognosis of patients, and to explore the influencing factors of inflammation and tumor microenvironment on the efficacy of neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer. To explore the predictors of neoadjuvant therapy in patients with esophageal squamous cell carcinoma.",[204],"Esophageal Cancer",[206,207,208,209,210],"neoadjuvant therapy","immunotherapy","overall survival","efficacy","safety","2024-11-20",{"date":213,"type":33},"2024-11-25",{"date":215,"type":33},"2023-05-04",{"date":143,"type":21},{"name":39,"class":40},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":229,"conditions":230,"keywords":232,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":41},"100509868","phase-3-a-study-of-chemoradiation-in-combination-with-tislelizumab-as-first-line-treatment-in-participants-with-advanced-esophageal-squamous-cell-carcinoma-100509868","NCT05919030","A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma","Chemoradiation Versus Chemotherapy in Combination with Tislelizumab As First Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Low PD-L1 Expression (RENMIN-236): Multicentre, Randomised, Phase 3 Trial","Inclusion Criteria:\n\n1. Subjects must have histologically confirmed squamous cell carcinoma of esophagus (per AJCC 8th edition).\n2. Subjects must have unresectable advanced, recurrent or metastatic ESCC.\n3. Subjects must not be amenable to curative approaches such as definitive chemoradiation and\u002For surgery.\n4. PD-L1 expression (CPS) is less than 10.\n5. No prior systemic anticancer therapy given as primary therapy for advanced or metastatic disease.\n6. ECOG Performance Status of 0 or 1.\n7. Subjects must have at least one measurable lesion by CT or MRI per RECIST 1.1 criteria; radiographic tumor assessment must be performed within 28 days prior to randomization.\n8. Subjects must have adequate organ and bone marrow function.\n\nExclusion Criteria:\n\n1. Presence of tumor cells in the brain or spinal cord which are symptomatic or require treatment.\n2. Active known or suspected autoimmune disease.\n3. Any serious or uncontrolled medical disorder or active infection.\n4. Known history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).\n5. Any positive test result for hepatitis B or C indicating acute or chronic infection and\u002For detectable virus.\n6. Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.",{"count":226,"type":21},155,[228],"PHASE3","This study is a multicentre, randomised, parallel-controlled, open-label, 3 phase clinical trial. The subjects were untreated, unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma with low PD-L1 expression. Patients were randomly assigned to receive chemoradiation or chemotherapy in combination with Tislelizumab at a ratio of 1: 1. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. We hypothesized that in advanced esophageal squamous cell carcinoma patients with low PD-L1 expression, chemoradiation versus chemotherapy in combination with Tislelizumab will significantly improve PFS.",[231],"Esophageal Squamous Cell Carcinoma",[233,234,235,236,237],"Chemoradiation","Immunotherapy","Advanced esophageal cancer","Low PD-L1 expression","Progression-free survival","2024-11-12",{"date":240,"type":33},"2024-11-14",{"date":242,"type":33},"2023-07-01",{"date":244,"type":21},"2027-07-01",{"name":39,"class":40},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":4,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":270},"100519159","effect-of-the-automatic-surveillance-system-on-surveillance-rate-of-patients-with-gastric-premalignant-lesions-100519159","NCT06039917","Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions","Inclusion Criteria:\n\n* Male or female aged 18 years or older who undergo upper endoscopy.\n\nExclusion Criteria:\n\n* 1)No contact information or invalid contact information.\n* 2\\) The surveillance interval cannot be determined according to the surveillance guidelines, including no upper gastrointestinal pathology, therapeutic endoscopy or with history of previous gastrectomy, esophagectomy, or ESD, no dysplasia degrees, no biopsy sites, non-epithelial lesions, duodenal lesions, ulcer and so on.\n* 3\\) Needless for surveillance or others.\n* 4\\) High-grade intraepithelial neoplasia or cancer of the esophagus or stomach.\n* 5\\) Low-grade intraepithelial neoplasia of the esophagus and Barrett's esophagus.\n* 6\\) High-risk diseases or other special conditions for which the patient is deemed unsuitable for clinical trials by the investigator.",{"count":253,"type":21},1460,[24],"In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of patients with gastric premalignant lesions. The enrolled patients were divided into group A with intelligent surveillance system, group B with manual reminder, and group C with natural state. The surveillance among the three groups will be compared.",[257,258],"Artificial Intelligence","Surveillance",[260,261],"surveillance rate","automatic surveillance","2024-11-01",{"date":264,"type":33},"2024-11-04",{"date":266,"type":33},"2023-09-10",{"date":268,"type":21},"2029-12-31",{"name":39,"class":40},4,{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":41},"100563347","phase-2-the-efficacy-and-safety-of-treatment-with-telitacicept-in-primary-membranous-nephropathy-100563347","NCT06614985","The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy","TEST-T-PMN","Inclusion Criteria:\n\n1. Patients must have a confirmed diagnosis of primary membranous nephropathy through renal biopsy to be eligible for inclusion in the study.\n2. Adult patients aged 18 years or older of any gender are eligible for inclusion in the study.\n3. Patients who meet the diagnostic criteria for nephrotic syndrome, which includes quantitative urine protein levels greater than 3.5 g\u002F24 h and serum albumin levels less than 30 g\u002FL, are eligible for inclusion in the study.\n4. Patients who meet the high-risk criteria for progression of membranous nephropathy based on the KDIGO (Kidney Disease: Improving Global Outcomes) guidelines are eligible for inclusion in the study. High-risk criteria include eGFR less than 60 mL\u002Fmin\u002F1.73 m2 and\u002For urine protein excretion greater than 8 g\u002Fday for at least 6 months, or normal eGFR with urine protein excretion greater than 3.5 g\u002Fday and urine protein reduction less than 50% after 6 months of ACEI\u002FARB treatment, with any of the following criteria: serum albumin less than 25 g\u002FL, anti-PLA2R antibody greater than 50 RU\u002FmL, urine α1-microglobulin greater than 40 μg\u002Fmin, urine IgG1 greater than 1 μg\u002Fmin, urine β2-microglobulin greater than 250 mg\u002Fday, and SI greater than 0.2.\n5. Participants are required to consent to use effective contraception methods with their partners throughout the entire duration of the study. Participants must have a thorough understanding of the nature, significance, potential benefits, inconveniences, and potential risks of the study and voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n1. Secondary membranous nephropathy patients (caused by autoimmune or infectious diseases, tumors, etc.);\n2. Patients with HIV infection, viral hepatitis, active liver disease (with ALT\u002FAST\u002Fbilirubin levels exceeding 3 times the upper limit of normal), or other severe infections;\n3. Patients with a rapid decline in eGFR (\\>15 mL\u002Fmin) during the screening period are excluded;\n4. Patients who have undergone kidney transplantation or other organ transplantation;\n5. Patients with a known allergy or hypersensitivity to the active ingredient of the investigational drug or any of the listed excipients;\n6. Patients with acute or critical cardiovascular or cerebrovascular diseases;\n7. Patients with immunodeficiency, hypoalbuminemia (IgG \\\u003C 400 mg\u002Fdl), or IgA deficiency (IgA \\\u003C 10 mg\u002FdL);\n8. Pregnant or lactating women;\n9. Patients diagnosed with malignant tumors within the past 5 years;\n10. Laboratory findings of severe abnormalities (Hb \\\u003C 80 g\u002FL, PLT \\\u003C 50,000\u002Fmm3, neutrophil count \\\u003C 1,000\u002Fmm3, etc.);\n11. Patients who have used steroids or immunosuppressive agents (including but not limited to corticosteroids, adrenocorticotropic hormones, azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine, biologic agents such as rituximab, etc.), cyclophosphamide, bortezomib, dexamethasone, Chinese medicines or preparations containing Tripterygium wilfordii, intravenous immunoglobulin, plasma exchange, leukapheresis, live vaccines, or other investigational drugs, etc., within 3 months prior to screening;\n12. Patients with other diseases or conditions that, in the opinion of the investigator, would render the patient unsuitable for participation in this study;",{"count":279,"type":21},172,[158],"This is a multiple-center, prospective, open-label, positive drug controlled, randomized, clinical study to evaluate the safety and efficacy of Telitacicept in the treatment of primary membranous nephropathy.",[283],"Primary Membranous Nephropathy","2024-09-23",{"date":286,"type":33},"2024-09-26",{"date":288,"type":21},"2024-10-20",{"date":290,"type":21},"2027-10-01",{"name":39,"class":40},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":17,"minAge":300,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":41},"100549127","metabolomic-profile-of-vitreoretinal-diseases-an-nmr-based-approach-using-vitreous-100549127","NCT06429969","Metabolomic Profile of Vitreoretinal Diseases: an NMR-Based Approach Using Vitreous.","Nuclear Magnetic Resonance (NMR)-Based Metabolomic Characterisation of Vitreoretinal Diseases Using Vitreous Fluid","NMR","Inclusion Criteria:\n\n1. Confirmation of IMH diagnosis with concomitant need for PPV surgery;\n2. Confirmation of DR diagnosis with concomitant need for PPV surgery;\n3. Confirmation of RD diagnosis with concomitant need for PPV surgery;\n4. Confirmation of IMM diagnosis with concomitant need for PPV surgery;\n5. Confirmation of RVO diagnosis with concomitant need for PPV surgery.\n\nExclusion Criteria:\n\n1. Diagnosed vitreoretinal disease with no need for PPV surgery;\n2. Previous history of PPV surgery;\n3. Combination of other active ophthalmic diseases, such as acute conjunctivitis and uveitis;\n4. Combination of serious systemic diseases such as hypertension and diabetes mellitus.","40 Years","90 Years",{"count":303,"type":21},450,"The goal of this observational study was to learn about metabolomics profiles in vitreoretinal diseases by nuclear magnetic resonance (NMR)using vitreous fluid. The main question it aimed to answer was abnormal biomarkers for common retinal diseases such as idiopathic macular hole(IMH), diabetic retinopathy(DR) and retinal detachment(RD). Participants would not be subjected to any intervention and the investigators would only collect preoperative information and remaining vitreous samples. The investigators divided the participants into groups with appropriate disease names based on the disease diagnosis, such as IMH group, DR group, and RD group. The MH group was used as a control group, investigators compared other groups to see the metabolomic abnormalities.",[306],"Vitreoretinal Disease","2024-05-21",{"date":309,"type":33},"2024-05-28",{"date":311,"type":33},"2024-01-17",{"date":313,"type":21},"2027-12-31",{"name":39,"class":40},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":41},"100533239","nutritional-psychological-intervention-and-vomit-free-management-on-survival-and-quality-of-life-in-advanced-gastrointestinal-tumors-100533239","NCT06223230","Nutritional Psychological Intervention and Vomit-free Management on Survival and Quality of Life in Advanced Gastrointestinal Tumors","Inclusion Criteria:\n\n1. Age 18-75, male or female;\n2. Patients with advanced esophageal cancer, gastric cancer, liver cancer and colorectal cancer and other gastrointestinal tumors diagnosed by pathological histology or cytology;\n3. Expected survival ³ 8 weeks and able to receive long-term follow-up;\n4. Eastern Cooperative Oncology Group(ECOG)-Performance Status(PS) score of 0-2;\n5. First-line treatment receiving standard oncology treatment and nutritional psychological intervention and vomit-free management group (study group); first-line treatment receiving only standard oncology treatment group (control group);\n6. Voluntarily signing an informed consent form.\n\nExclusion Criteria:\n\n1. Other malignant tumors diagnosed within the previous 5 years, except for effectively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or effectively resected in situ cervical cancer or breast cancer;\n2. history of psychiatric illness prior to the diagnosis of the tumor\n3. patients who resist treatment\n4. patients with poorly controlled severe heart disease, liver or kidney insufficiency, severe anemia, multiple lymph node enlargement, leukopenia, etc;\n5. patients who are pregnant or have a pregnancy plan;\n6. patients who, in the judgment of the investigator, are not suitable for inclusion in this study.","75 Years",{"count":323,"type":21},316,[24],"Aims to observe and evaluate the impact of survival and quality of life of patients with gastrointestinal tumors such as advanced esophageal, gastric, liver, pancreatic, and colorectal cancers through nutritional-psychological interventions versus no-vomit management compared to standard antitumor therapy alone",[327,328],"Digestive System Cancer","Digestive System Neoplasm","2024-01-28",{"date":331,"type":33},"2024-01-30",{"date":333,"type":33},"2022-06-01",{"date":335,"type":21},"2026-06-30",{"name":39,"class":40},{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":154,"sex":17,"minAge":18,"maxAge":127,"enrollmentInfo":345,"targetDuration":347,"studyType":107,"phases":4,"briefSummary":348,"conditions":349,"keywords":351,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":41},"100528550","wuhan-high-myopia-study-100528550","NCT06162234","Wuhan High Myopia Study","Long Term Observation of Ocular Structure and Visual Function in Eyes With High Myopia：Wuhan High Myopia Study","LOVE-WH","Inclusion Criteria:\n\n* Voluntarily sign informed consent;\n* Commit to follow the research procedures and cooperate with the whole process of the study;\n* Age ≥18 years old;\n* Best corrected visual acuity ≥0.1;\n* Spherical Equivalent Refraction≤-6.00D or axial length ≥26mm in high myopia group；\n\nExclusion Criteria:\n\n* Unable or unwilling to sign informed consent;\n* Unable to cooperate with the examination;\n* Astigmatism ≤-1.5D；\n* Patients with refractive interstitial opacity so that fundus images cannot be collected；\n* Patients with fundus diseases such as diabetic retinopathy, hypertensive retinopathy, age-related macular degeneration, retinal vein obstruction, retinal artery obstruction, etc",{"count":346,"type":21},1000,"4 Years","The study aims to observe the long-term changes of ocular（especially fundus） structure and visual function in patients with high myopia, so as to provide evidence for the prevention, diagnosis and prognosis of high myopia.",[350],"High Myopia",[352,353],"ocular biometric parameters","Refractive Errors","2023-12-19",{"date":356,"type":33},"2023-12-27",{"date":358,"type":21},"2023-12-25",{"date":360,"type":21},"2027-09-01",{"name":39,"class":40},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":22,"phases":370,"briefSummary":371,"conditions":372,"keywords":373,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":380,"locationsCount":41},"100508011","effect-of-the-automatic-surveillance-system-on-surveillance-rate-of-colorectal-postpolypectomy-patients-100508011","NCT05894850","Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients","Inclusion Criteria:\n\n* Male or female aged 18 years or older who undergo colonoscopy.\n\nExclusion Criteria:\n\n* 1)No pathological result.\n* 2\\) No or invalid contact information.\n* 3\\) The surveillance interval cannot be determined according to the surveillance guidelines, including poor bowel preparation, colorectal cancer or suspicious malignance, surgery or colorectal ESD history, those who fail to complete colonoscopy due to unbearable, pathological indications of not polyps, hamartoma or lymphoma polyps, history of ulcerative colitis, and so on.\n* 4\\) Has participated in other clinical trials, signed the informed consent form and is in the surveillance period of other clinical trials.\n* 5\\) Have drug or alcohol abuse or psychological disorder in the past five years.\n* 6）Pregnancy.\n* 7）Not suitable for recruitment after investigator evaluation because of other high-risk conditions.",{"count":369,"type":21},1644,[24],"In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of colorectal postpolypectomy patients. The enrolled patients were divided into group A with intelligent surveillance system reminding though telephone and message, group B with intelligent surveillance system reminding though message, group C with manual reminder, and group D with natural state. The surveillance among the four groups were compared.",[257,258],[260,261],"2023-06-07",{"date":376,"type":33},"2023-06-08",{"date":378,"type":21},"2023-06-01",{"date":268,"type":21},{"name":39,"class":40},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":392,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":399,"locationsCount":400},"100497021","evaluating-the-effect-of-the-automatic-surveillance-system-on-surveillance-rate-of-colorectal-postpolypectomy-patients-100497021","NCT05751824","Evaluating the Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients","Evaluating the Effect of the Automatic Surveillance System on Surveillance Rate of Colorectal Postpolypectomy Patients: A Prospective, Multicenter Study",{"count":388,"type":21},867,[24],"In this study, we proposed a prospective study about the effect of the automatic surveillance system on surveillance rate of colorectal postpolypectomy patients. The enrolled patients were divided into group A with intelligent surveillance system, group B with manual reminder, and group C with natural state. The surveillance among the three groups were compared.",[257,258],[260,261],"2023-03-07",{"date":395,"type":33},"2023-03-09",{"date":397,"type":21},"2023-02-26",{"date":268,"type":21},{"name":39,"class":40},2,{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":321,"enrollmentInfo":408,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":41},"100482513","phase-2-short-course-radiotherapy-combined-with-neoadjuvant-chemotherapy-and-pd-1-inhibitor-in-the-treatment-of-locally-advanced-gastric-adenocarcinoma-100482513","NCT05563012","Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma","Single-arm Phase II Clinical Study of Short-course Radiotherapy Combined With Neoadjuvant Chemotherapy and PD-1 Inhibitor in the Treatment of Locally Advanced Gastric Adenocarcinoma","Inclusion Criteria:\n\n1. All individuals recruited signed a written informed consent;\n2. Aged between 18 and 75 years;\n3. Histologically confirmed gastric adenocarcinoma, and Stage III (cT3-4aN1-3 M0, American Joint Committee on Cancer (AJCC) TNM staging system 8th edition) gastric cawas confirmed by enhanced CT\u002FMRI scan (endoscopic ultrasonography (EUS) and laparoscopic exploration if necessary), and the lesion was resectable;\n4. No previous systemic therapy, including including surgery, radiotherapy, chemotherapy and immunotherapy, etc；\n5. Patients who have no contraindications and consent to radical surgery;\n6. Eastern Cooperative Group (ECOG) performance status score 0 or 1;\n7. Expected survival time \\> 6 months;\n8. The main organ function of cases should be normal, and meet the following criteria: ①Absolute neutrophil count (ANC)≥1.5×109\u002FL (no Granulocyte colony-stimulating factor within 14 days prior to enrolment); ②Platelets ≥100×109\u002FL (no blood transfusion within 14 days prior to enrolment); ③Hemoglobin\\>90g\u002FL (no blood transfusion or no erythropoietin (EPO) dependence within 14 days prior to enrolment); ④Total bilirubin (TBIL) ≤1.5 x upper limit of normal (ULN), such as total bilirubin \\> 1.5 x ULN but direct bilirubin ≤1.5 x ULN was also allowed to be enrolled; ⑤ALT (glutamic-pyruvic transaminase) and AST (glutamic-oxalacetic transaminase) ≤2.5 × ULN; ⑥Serum Cr≤1.5 × ULN and creatinine clearance ≥60 ml\u002Fmin (Cockcroft-Gault formula); ⑦International normalized ratio (INR) \\\u003C1.5 or prothrombin time (PT)≤1.5 ULN; ⑧Thyroid stimulating hormone (TSH) was normal. If TSH was abnormal, subjects with total T3 (or FT3) and FT4 normal could also be enrolled; ⑨Myocardial infarction was normal.\n9. Female subjects of reproductive age must conduct pregnancy test (serum or urine) within 3 days before the first study drug administration (day 1 of cycle 1), and the results are negative. If the urine pregnancy test result cannot be confirmed as negative, a blood pregnancy test is requested. Women of non-reproductive age were defined as those who had been postmenopausal for at least 1 year or who had undergone surgical sterilization or hysterectomy;\n10. If there was a risk of conception, all subjects (male or female) were required to use contraception with an annual failure rate of less than 1% for the entire treatment period until 120 days after the last administration of the test drugs (or 180 days after the last administration of the chemotherapy drug ).\n\nExclusion Criteria:\n\n1. Other malignancy disease history within five years, with the exception of basal cell carcinoma or squamous carcinoma of skin, and carcinoma in situ that have undergone radical resection;\n2. Endoscopic signs of active bleeding in the lesion;\n3. Is participating in an interventional clinical study or has received another study drug or used a study device within 4 weeks before the first study drug administration;\n4. Prior treatment with an anti-PD-1, anti-PD-L1 or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g. CTLA-4, OX40, CD137) drugs;\n5. Systemic systemic therapy with Chinese patent drugs or immunomodulatory agents (including thymosin, interferon, and interleukin, except for local use to control pleural effusion) with anti-tumor indications was received within 2 weeks before the first study drug administration;\n6. Active autoimmune disease requiring systemic therapy (e.g., use of disease-modifying agents, glucocorticoids, or immunosuppressants) occurred within 2 years before the first study drug administration. Replacement therapy (e.g., thyroxine, insulin, or physiologic glucocorticoids for adrenal or pituitary insufficiency) is not considered a form of systemic treatment;\n7. Had received systemic glucocorticoid therapy (excluding nasal, inhaled, or other local glucocorticoids) or any other form of immunosuppressive therapy within 7 days before the first study drug administration;\n8. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;\n9. Known allergy to drugs used in this study;\n10. Unable to intake Capecitabine orally (such as the inability to swallow and intestinal obstruction);\n11. Failure to recover from treatment-related toxicity\u002Fcomplications to baseline or grade-1 AEs (except for fatigue and hair loss);\n12. Has a known history of HIV infection (HIV 1\u002F2 antibody positive);\n13. Untreated active hepatitis B (defined as HBsAg-positive with a detected HBV-DNA copy number greater than the upper limit of normal values in the laboratory at the study center); Note: Hepatitis B subjects who meet the following criteria can also be enrolled: ①With HBV viral load \\\u003C1000 copies \u002Fml (200 IU\u002Fml) before the first study drug administration, subjects should receive anti-HBV therapy to avoid virus reactivation throughout the study chemotherapy drug treatment; ②For subjects with anti-HBC (+), HBsAg (-), anti-HBs (-), and HBV viral load (-), prophylactic anti-HBV therapy is not required, but monitoring of viral reactivation is required;\n14. Active HCV-infected subjects (HCV antibody positive with HCV-RNA levels higher then the lower limit of detection);\n15. Had received live vaccine within 30 days before the first study drug administration; Note: Inactivated virus vaccine for injection against seasonal influenza is permitted for 30 days before the first study drug administration; However, live attenuated influenza vaccines administered intranasally are not allowed;\n16. Pregnant or lactating women;\n17. The presence of any severe or uncontrolled systemic disease, e.g; ①The resting ECG showed significant abnormalities in rhythm, conduction or morphology with severe symptoms and difficult to control, such as complete left bundle branch block, degree ⅱ higher heart block, ventricular arrhythmia or atrial fibrillation; ②Unstable angina pectoris, congestive heart failure, New York Heart Association (NYHA) grade ≥ 2 chronic heart failure; ③Any arterial thrombosis, embolism, or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack, occurred in the 6 months prior to enrollment; ④Poor blood pressure control (systolic blood pressure \\> 140 mmHg, diastolic blood pressure \\> 90 mmHg); ⑤Has a history of noninfectious pneumonia requiring glucocorticoid therapy within 1 year before the first study drug administration or active interstitial lung disease; ⑥Active pulmonary tuberculosis; ⑦Have active or uncontrolled infections requiring systemic therapy; ⑧There are active diverticulitis, abdominal abscess, and gastrointestinal obstruction; ⑨Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis; ⑩Poor diabetes control (fasting blood glucose (FBG) \\> 10mmol\u002FL); ⑪Urine routine indicated urinary protein ≥++, and 24-hour urinary protein \\> 1.0 g on urine dipstick; ⑫Patients with mental disorders who are unable to actively cooperate with treatment;\n18. Subjects are not eligible to participate in the study if they have abnormal medical history or evidence of disease, treatment or laboratory test values that may interfere with the results of the trial or prevent their full participation in the study, or if they have other conditions or potential risks that the investigator considers inappropriate for enrollment.",{"count":409,"type":21},29,[158],"This is a Prospective, Single-center, Single-arm, phase II clinical trial to explore the efficacy and safety of sintilimab (PD1 inhibitor) combined with XELOX chemotherapy, evaluate the pathological complete response rate of short-course radiotherapy combined with sintilimab and XELOX chemotherapy in neoadjuvant therapy for locally advanced gastric adenocarcinoma.",[413],"Disorder in Complete Remission in Response to Treatment","2022-09-28",{"date":416,"type":33},"2022-10-03",{"date":418,"type":33},"2022-09-26",{"date":420,"type":21},"2026-10-01",{"name":39,"class":40},{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":429,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":41},"100360424","samples-procurement-for-colorectal-cancer-gastric-cancer-and-non-malignant-disease-100360424","NCT03972956","Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease","Samples Procurement for Patients With Colorectal Cancer, Gastric Cancer, and Non-malignant Disease Undergoing Surgery","Inclusion Criteria:\n\n* Any patient diagnosed with colorectal cancer, gastric cancer, non-malignant disease that requires undergoing surgery.\n* Must be willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Subjects whose comorbidities would preclude diagnostic or therapeutic intervention.",{"count":346,"type":21},"The purposes of this study are to collect and store samples including blood, normal and tumor tissue from patients with colorectal cancer or gastric cancer, to collect and store samples including blood and\u002For normal gastrointestinal tissue (if available) from patients with non-malignant disease (including, but not limited to, inflammatory bowel disease (IBD), gastric ulcer, hemorrhoids or hernia), and to create a database for the collected samples and allow access to relevant clinical information for current and future protocols.",[432,433,434,435,436,437],"Colorectal Cancer","Gastric Cancer","Inflammatory Bowel Diseases","Gastric Ulcer","Hemorrhoids","Hernia","2022-04-28",{"date":440,"type":33},"2022-04-29",{"date":442,"type":33},"2020-12-23",{"date":444,"type":21},"2026-12-23",{"name":39,"class":40},{"id":447,"slug":448,"hasResults":11,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":4,"eligibilityCriteria":452,"healthyVolunteers":154,"sex":17,"minAge":18,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":456,"conditions":457,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":41},"100295529","genetic-and-epigenetic-determinants-of-response-to-fluorouracil-based-adjuvant-chemotherapy-in-patients-with-stage-iii-colorectal-cancer-100295529","NCT03127111","Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer","The Identification, Validation and Implementation of Molecular Markers to Predict Response to Fluorouracil-based Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients - Prospective Clinical Observational Study","Inclusion Criteria:\n\n1. Requirements for tumor parameters\n\n   1. Histologically confirmed colorectal adenocarcinoma.\n   2. Stage III disease (any pT, N1-2, M0).\n   3. Tumors must have been curatively resected (R0).\n   4. No evidence of residual involved lymph node disease or metastatic disease at the time of registration.\n2. Requirements for patient characteristics\n\n   1. Patient is ≥ 18 years of age on the day of consenting to the study.\n   2. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1 at the time of screening.\n   3. Fertile patients must use effective contraception.\n   4. Patients must demonstrate ability to understand and the willingness to sign a written informed consent document.\n   5. Patients must demonstrate ability to complete study questionnaires.\n   6. Patients must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up.\n3. Required initial laboratory values\n\n   1. Leukocytes ≥ 3,000\u002Fmm\\^3\n   2. Absolute neutrophil count ≥ 1,500\u002Fmm\\^3\n   3. Platelet count ≥ 100,000\u002Fmm\\^3\n   4. Creatinine ≤ 1.5 times upper limit of normal (ULN)\n   5. Total Bilirubin ≤ 1.5 times ULN\n   6. Aspartate aminotransferase (AST) ≤ 2.5 times ULN\n   7. Alanine aminotransferase (ALT) ≤ 2.5 times ULN\n\nExclusion Criteria:\n\n1. Patients with a known history of allergic reactions attributed to compounds of similar chemical or biologic composition to fluorouracil.\n2. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection-requiring intravenous antibiotics, or psychological, familial, sociological, or geographical condition that would limit compliance with study requirements\n3. Following cardiovascular conditions within the past 6 months: Myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia, cerebrovascular accident or transient ischemic attack, deep vein thrombosis, other significant thromboembolic event.\n4. Known human immunodeficiency virus (HIV)-positive patients and those with known hepatitis B or C.\n5. Patients with evidence of other primary malignancies within the past 5 years, excluding adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix.\n6. Pregnant or nursing.","70 Years",{"count":455,"type":21},300,"The goal of this laboratory research is to look for genetic and epigenetic markers that can predict which patients with stage III colorectal cancer will benefit from fluorouracil-based adjuvant chemotherapy.",[458],"Stage III Colorectal Cancer","2022-03-12",{"date":461,"type":33},"2022-03-15",{"date":463,"type":21},"2022-12-01",{"date":465,"type":21},"2026-12-31",{"name":39,"class":40},{"id":468,"slug":469,"hasResults":11,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":474,"minAge":18,"maxAge":453,"enrollmentInfo":475,"targetDuration":4,"studyType":22,"phases":477,"briefSummary":478,"conditions":479,"keywords":481,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":41},"100443048","multicenter-study-on-postoperative-urinary-and-sexual-function-during-laparoscopic-functional-total-mesorectum-excision-100443048","NCT05049317","Multicenter Study on Postoperative Urinary and Sexual Function During Laparoscopic Functional Total Mesorectum Excision","A Prospective, Multicenter Clinical Study of Preservative Effect on Postoperative Urinary and Sexual Function During Laparoscopic Functional Total Mesorectum Excision for Male Rectal Cancer Patients","Inclusion Criteria:\n\n1. Male, 18-70 years of age, informed consent;\n2. Tumors from anal edge 6 \\~ 12 cm (measured by rigid proctoscope);\n3. Rectal cancer confirmed pathologically by endoscopic biopsy;\n4. Preoperative cT1-3aN0M0 stage (ESMO, 2013);\n5. Ro resection is expected;\n6. Normal urinary function, normal erection function and ejaculation function grading as I level;\n\nExclusion Criteria:\n\n1. History of abdominal and pelvic major surgery;\n2. Emergency surgery is needed due to the complication (bleeding, obstruction, or perforation) caused by rectal cancer;\n3. Pelvic or distant metastasis;\n4. Neoadjuvant radiotherapy or chemoradiotherapy;\n5. No sexual life;","MALE",{"count":476,"type":21},88,[24],"Urinary and sexual dysfunctions are among the most common complications in rectal cancer surgery. The aim of this study was to investigate the protective effect of laparoscopic functional total mesorectum excision (FTME) on urinary and sexual function in male patients with mid-low rectal cancer. This is a prospective, single-arm, multicenter, uncontrolled, clinical study in 88 eligible subjects with mid-low rectal cancer. After informed consent, eligible patients will be performed laparoscopic FTME surgery. Patients' demographic, operative detail, postoperative outcomes and follow-up will be recorded prospectively.",[480],"Rectal Cancer",[480,482,483,484,485],"Nerve plane","Sexual dysfunction","Urinary dysfunction","Total mesorectal excision","2021-10-28",{"date":488,"type":33},"2021-11-01",{"date":490,"type":21},"2021-11-24",{"date":492,"type":21},"2028-09-24",{"name":39,"class":40},""]